Poseida Therapeutics. has filed a patent for compositions and methods that allow for directing proteins to specific locations in the genome of an organism. The patent describes the use of fusion proteins, such as dSaCas9-Clo051 and dCas9-Clo051, to achieve this. The method involves providing a composition containing a DNA localization component and an effector molecule, which can be a nucleic acid encoding the components. The DNA localization component includes at least one guide RNA (gRNA), while the effector molecule consists of an inactivated Cas9 (dCas9) or an inactivated nuclease domain, along with Clo051 or a nuclease domain. GlobalData’s report on Poseida Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
According to GlobalData’s company profile on Poseida Therapeutics, Cytokine activate T-cell based compositions was a key innovation area identified from patents. Poseida Therapeutics's grant share as of September 2023 was 24%. Grant share is based on the ratio of number of grants to total number of patents.
The patent is filed for directing proteins to specific loci in a genome
A recently filed patent (Publication Number: US20230257737A1) describes a method for directing proteins to specific locations in the genome of an organism. The method involves providing a composition containing a DNA localization component and an effector molecule, or a nucleic acid encoding these components. The DNA localization component includes at least one guide RNA (gRNA), while the effector molecule is a fusion protein consisting of an inactivated Cas9 (dCas9) or an inactivated nuclease domain, along with Clo051 or a nuclease domain.
The method can be applied to genomic DNA sequences in vivo, ex vivo, or in vitro, and is not limited to human genomic DNA sequences. It can be used to modify the genome of an organism by bringing the composition or nucleic acid into contact with a genomic DNA sequence or base pair. This contact can be achieved through fluid communication, and the genomic sequence or base pair may be separated by the activity of an endonuclease.
The method allows for various modifications to the genomic sequence or base pair, including deletion, insertion, substitution, inversion, and relocation. These modifications can be induced by a DNA repair mechanism. In the case of insertion, an exogenous, artificial, or heterologous sequence can be inserted into the genomic sequence, which may be non-naturally occurring.
The patent also covers the resulting modified genomic sequence and cells containing this sequence. The modification can occur in vivo, ex vivo, or in vitro, and the cells can be pluripotent stem cells, embryonic stem cells, or induced pluripotent stem cells. The method is not limited to human cells or human embryonic cells.
In summary, this patent describes a method for directing proteins to specific loci in a genome using a DNA localization component and an effector molecule. The method allows for various modifications to the genomic sequence and can be applied to a wide range of organisms and cell types. The patent also covers the resulting modified genomic sequence and cells.
To know more about GlobalData’s detailed insights on Poseida Therapeutics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
